ALFA Filings
Every announcement, straight from the exchange
Every AstraZeneca Pharma India regulatory approval announcement on NSE and BSE, newest first, each with its own page.
Time
6 announcements
AstraZeneca Pharma received CDSCO permission to market 'Enhertu' for an additional breast cancer indication in India. This expands the drug's therapeutic usage under regulatory approval.
AstraZeneca Pharma India Limited received CDSCO approval to import and market Enhertu for an additional breast cancer indication. This regulatory milestone enables the treatment's use for HER2-positive adult patients.
AstraZeneca Pharma India received CDSCO approval to market Benralizumab (Fasenra) for treating Hypereosinophilic Syndrome. This regulatory clearance expands the drug's therapeutic indications in the Indian market.
AstraZeneca Pharma received CDSCO approval to market Enhertu for an additional breast cancer indication in India. This regulatory milestone expands the drug's therapeutic reach and commercial potential.
AstraZeneca Pharma India received CDSCO approval to market Calquence for treating previously untreated mantle cell lymphoma. This expands the drug's Indian market indications for adult patients.
AstraZeneca Pharma India Ltd received CDSCO approval to import and market Calquence (Acalabrutinib 100mg) for treating previously untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma. This additional indication expands the drug's therapeutic reach in the Indian market, subject to final statutory approvals.